EAS 2020 Four-weekly injection of the recombinant fusion protein LIB003 that binds stably to PCSK9 reduced LDL-c, observed in a one year extension study.

EAS 2020 In participants of the UK Biobank, a LPA genetic risk score and measured Lp(a) levels provided comparable risk prediction for ASCVD risk in a primary prevention setting.

EAS 2020 Inhibition of ANGPTL3 with evinacumab reduced LDL-c levels significantly in HoFH patients with little to no LDL receptor function.

EAS 2020 A post-hoc analysis of the ELIPSE HoFH trial in patients with little to no LDL receptor activity demonstrated a large reduction of LDL-c with the ANGPTL3 inhibitor evinacumab compared to placebo.

EAS 2020 In a cohort of high-risk primary prevention individuals, 6-monthly injections with inclisiran reduced LDL-c and other atherogenic lipoproteins compared to placebo.

EAS 2020 A subanalysis of ORION-9 showed that lowering of LDL-c by inclisiran was similar across subgroups of genotypes in those with heterozygous FH.

EAS 2020 Prof. Stein gives an overview of studies with the small binding protein targeting PCSK9, named LIB003.

EAS 2020 A subanalysis of the ORION-9 trial demonstrated that across subgroups of genotypes for heterozygous FH, inclisiran was equally effective in reducing LDL-c.